Usage Patterns of Stop Smoking Medications in Australia, Canada, the United Kingdom, and the United States: Findings from the 2006–2008 International Tobacco Control (ITC) Four Country Survey
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Varenicline is a new prescription stop smoking medication (SSM) that has been available in the United States since August 1, 2006, in the United Kingdom and other European Union countries since December 5, 2006, in Canada since April 12, 2007, and in Australia since January 1, 2008. There are few population-based studies that have examined use rates of varenicline and other stop smoking medications. We report data from the ITC Four Country survey conducted with smokers in the US, UK, Canada, and Australia who reported an attempt to quit smoking in past year in the 2006 survey (n = 4,022 participants), 2007 (n = 3,790 participants), and 2008 surveys (n = 2,735 participants) Respondents reported use of various stop smoking medications to quit smoking at each survey wave, along with demographic and smoker characteristics. The self-reported use of any stop smoking medication has increased significantly over the 3 year period in all 4 countries, with the sharpest increase occurring in the United States. Varenicline has become the second most used stop smoking medication, behind NRT, in all 4 countries since being introduced. Between 2006 and 2008, varenicline use rates increased from 0.4% to 21.7% in the US, 0.0% to 14.8% in Canada, 0.0% to 14.5% in Australia, and 0.0% to 4.4% in the UK. In contrast, use of NRT and bupropion remained constant in each country. Males and non-whites were significantly less likely to report using any SSM, while more educated smokers were significantly more likely to use any SSM, including varenicline. Our findings suggest that the introduction of varenicline led to an increase in the number of smokers who used evidence-based treatment during their quit attempts, rather than simply gaining market share at the expense of other medications. From a public health perspective, messages regarding increased success rates among medication users and the relative safety of stop smoking medications should be disseminated widely so as to reach all smokers of all socioeconomic classifications equally.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The American Dental Hygienists Association recommends that oral health providers: Ask patients about tobacco use, Advise quitting tobacco use, and Refer to state quitlines (Ask-Advise-Refer; AAR).”
From A National Dental Practice-Based Research Network phase II, cluster-randomized clinical trial assessing nicotine replacement therapy sampling in dental settings: study protocol for the Free Samples for Health (FreSH) study (2024) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treating Tobacco Use and Dependence: 2008 Update: (566222009-001)
(2009) · PsycEXTRA Dataset · doi:10.1037/e566222009-001 · Cited by 3,046 · cited 2×
“Given the number of pharmacotherapies shown to be effective in aiding smoking cessation attempts, United States Clinical Practice Guidelines recommend the use of pharmacotherapy for all smokers who want to make a quit attempt, so as long as no contraindications for medication use are present [5,7].”
BackgroundTreating Tobacco Use and Dependence
(2008) · Pediatrics · doi:10.1542/peds.2008-1627 · Cited by 2,697
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464 · cited 1×
“Pharmacological treatments such as nicotine replacement therapy (NRT), sustained-release bupropion, and varenicline are effective in terms of diminishing the severity of withdrawal symptoms and reducing the chance of relapse in smokers who make a quit attempt [1-4].”
BackgroundShape of the relapse curve and long-term abstinence among untreated smokers
Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414 · cited 2×
“Pharmacological treatments such as nicotine replacement therapy (NRT), sustained-release bupropion, and varenicline are effective in terms of diminishing the severity of withdrawal symptoms and reducing the chance of relapse in smokers who make a quit attempt [1-4].”
BackgroundInfluentialNicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Nicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 861
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Tobacco in Australia : facts and issues 1995
Winstanley, M. H., Woodward, S. D., & Walker, N. (1995) · Medical Entomology and Zoology · Cited by 694
The English smoking treatment services: one‐year outcomes
Ferguson, J., Bauld, L., Chesterman, J., & Judge, K. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01028.x · Cited by 347 · cited 4×
“In the United Kingdom, the government provides stop smoking medications through the National Health Service prescription program [6] and the NHS Stop Smoking Services.”
BackgroundInfluentialMethods of the International Tobacco Control (ITC) Four Country Survey
Thompson, M. E., Fong, G. T., Hammond, D., Boudreau, C., Driezen, P., Hyland, A., Borland, R., Cummings, K. M., Hastings, G. B., Siahpush, M., et al. (2006) · Tobacco Control · doi:10.1136/tc.2005.013870 · Cited by 340 · cited 1×
“The objective of the International Tobacco Control (ITC) Project is to evaluate effects of national-level and sub-national tobacco control policies [17].”
BackgroundSelf-citationTønnesen, P., Carrozzi, L., Fagerström, K. O., Gratziou, C., Jimenez-Ruiz, C., Nardini, S., Viegi, G., Lazzaro, C., Campell, I. A., Dagli, E., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00060806 · Cited by 254 · cited 1×
“Pharmacological treatments such as nicotine replacement therapy (NRT), sustained-release bupropion, and varenicline are effective in terms of diminishing the severity of withdrawal symptoms and reducing the chance of relapse in smokers who make a quit attempt [1-4].”
BackgroundNicotine receptor partial agonists for smoking cessation (Review)
Cahill, K., Lf, S., & Lancaster, T. (2007) · Cited by 205
Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009) · BMJ · doi:10.1136/bmj.b3805 · Cited by 200
Fiore, M. C., & Staff, G. P. A. (2000) · Respiratory Care · doi:10.1177/002013240004501006 · Cited by 177 · cited 1×
“Given the number of pharmacotherapies shown to be effective in aiding smoking cessation attempts, United States Clinical Practice Guidelines recommend the use of pharmacotherapy for all smokers who want to make a quit attempt, so as long as no contraindications for medication use are present [5,7].”
BackgroundPublic health benefit of over-the-counter nicotine medications
Shiffman, S., Gitchell, J., Pinney, J. M., Burton, S. L., Kemper, K. E., & Lara, E. A. (1997) · Tobacco Control · doi:10.1136/tc.6.4.306 · Cited by 149 · cited 1×
“NRT in the form of gum, patch, and lozenge has been available over the counter without a prescription in the United States since 1996 [12].”
BackgroundIMPACT OF NICOTINE REPLACEMENT THERAPY ON SMOKING BEHAVIOR
Cummings, K. M., & Hyland, A. (2005) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.26.021304.144501 · Cited by 131
Self-citationImpact of UK policy initiatives on use of medicines to aid smoking cessation
West, R., DiMarino, M. E., Gitchell, J., & McNeill, A. (2005) · Tobacco Control · doi:10.1136/tc.2004.008649 · Cited by 92 · cited 1×
“Historically, the most common pharmacotherapy used in smoking cessation was nicotine replacement medication, such as the nicotine patch and nicotine gum [10,11].”
BackgroundSelf-citationUse of FDA-approved pharmacologic treatments for tobacco dependence--United States, 1984-1998.
Burton, S. L., Gitchell, J. G., & Shiffman, S. S. (2000) · PubMed · Cited by 88
Adverse effects and tolerability of medications for the treatment of tobacco use and dependence
Hays, J. T., & Ebbert, J. O. (2010) · Drugs · doi:10.2165/11538190-000000000-00000 · Cited by 74 · cited 1×
“However, other data does not suggest that serious adverse events with varenicline have been experienced beyond what would be expected in a large population of users [24].”
BackgroundHubbard, R. (2005) · Thorax · doi:10.1136/thx.2005.041798 · Cited by 62 · cited 1×
“This publicity caused a reduction in bupropion use which has remained very low ever since [18].”
BackgroundImpact of symptoms experienced by varenicline users on tobacco treatment in a real world setting
Halperin, A. C., McAfee, T. A., Jack, L. M., Catz, S. L., McClure, J. B., Deprey, T. M., Richards, J., Zbikowski, S. M., & Swan, G. E. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2008.09.001 · Cited by 52 · cited 1×
“A previous report indicated that adverse events, which can lead to discontinuation, are commonly reported among varenicline users [23].”
BackgroundCooper, J., Borland, R., & Yong, H. (2011) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1753-6405.2011.00733.x · Cited by 38
Self-citationPrescribing of smoking cessation medication in England since the introduction of varenicline
Langley, T. E., Huang, Y. S., McNeill, A. D., Coleman, T. J., Szatkowski, L., & Lewis, S. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03426.x · Cited by 35 · cited 2×
“One possibility is that the studies used different methodologies: in this study self report of SSM usage among quit attempters is used, wheras in the other UK study [19], medical records of prescriptions issued to all patients are considered.”
MethodResultSelf-citationMetzger, K. B., Mostashari, F., & Kerker, B. D. (2005) · American Journal of Public Health · doi:10.2105/ajph.2004.048025 · Cited by 29 · cited 1×
“The inclusion of OTC medications in our study may have accounted for the increase in SSMs overall in the UK and this increase may partly be due to the introduction of smokefree legislation in the UK in 2007, as such legislation has been shown to increase SSM purchases over the counter in other countries [20,21].”
BackgroundThe impact of the 2006 Scottish smoke-free legislation on sales of nicotine replacement therapy
Lewis, S., Haw, S. J., & McNeill, A. D. (2008) · Nicotine & Tobacco Research · doi:10.1080/14622200802443510 · Cited by 18 · cited 1×
“The inclusion of OTC medications in our study may have accounted for the increase in SSMs overall in the UK and this increase may partly be due to the introduction of smokefree legislation in the UK in 2007, as such legislation has been shown to increase SSM purchases over the counter in other countries [20,21].”
BackgroundSelf-citationCurrent and emerging treatment approaches for tobacco dependence
Cummings, K. M., & Mahoney, M. C. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0077-6 · Cited by 13 · cited 1×
“Varenicline has been available in the United States since August 1, 2006 and in the United Kingdom since December 5, 2006 [16].”
BackgroundSelf-citation
Cited by
Baker, T. B., Piper, M. E., Stein, J. H., Smith, S. S., Bolt, D. M., Fraser, D. L., & Fiore, M. C. (2016) · JAMA · doi:10.1001/jama.2015.19284 · Cited by 180
Carpenter, M. J. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.492 · Cited by 136
Long-term Nicotine Replacement Therapy: A Randomized Clinical Trial
Schnoll, R. A., Goelz, P. M., Veluz-Wilkins, A., Blazekovic, S., Powers, L., Leone, F. T., Gariti, P., Wileyto, E. P., & Hitsman, B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.8313 · Cited by 118
Kasza, K. A., Hyland, A. J., Borland, R., McNeill, A. D., Bansal‐Travers, M., Fix, B. V., Hammond, D., Fong, G. T., & Cummings, K. M. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04009.x · Cited by 85
Self-citationCarpenter, M. J., Jardin, B. F., Burris, J. L., Mathew, A. R., Schnoll, R. A., Rigotti, N. A., & Cummings, K. M. (2013) · Drugs · doi:10.1007/s40265-013-0038-y · Cited by 76
“The availability of varenicline in 2006 appears to have led to wider usage of evidence-based treatment [10, 11], but on the whole, the use of evidence-based pharmacotherapy remains the exception rather than the norm.”
Self-citation
Metadata
- Authors
- Fix, B. V., Hyland, A., Rivard, C., McNeill, A., Fong, G. T., Borland, R., Hammond, D., & Cummings, K. M.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- University of Nottingham (GB)
- Ontario Institute for Cancer Research (CA)
- Cancer Council Victoria (AU)
- University of Waterloo (CA)
- Corresponding author
- Fix, Brian V.
- ORCID
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2011-01-20
- Volume
- 8
- Issue
- 1
- Pages
- 222-233
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC3037071
- OpenAlex
- W2134235121
- Cited by
- 35
- References
- 29
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 6 · 2012: 2
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Cancer Research UK (450110, 014578, C312/A3726, 265903, 57897, 045734)
- Canadian Institutes of Health Research (C312/A3726, 014578, 265903, 045734, 79551, 450110, 57897)
- Medical Research Council
- Economic and Social Research Council (ES/G007489/1)
- National Health and Medical Research Council (014578, 450110, 045734, 57897, 265903, C312/A3726)
- National Cancer Institute (450110, C312/A3726, 045734, 57897, P01CA138389, 265903, R01CA100362, P50-CA111326, R01CA125116, 014578, P30CA016056)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- varenicline, nicotine replacement therapy, bupropion, smoking cessation, drug use trends, evidence-based treatment, Australia, Canada, United Kingdom, United States
- MeSH terms
- Varenicline, Adult, Age Factors, Australia, Benzazepines, Canada, Cross-Sectional Studies, Cross-Cultural Comparison, Drug Utilization, Female, United Kingdom, Health Surveys, Humans, International Cooperation, Male, Prospective Studies, Quinoxalines, Sex Factors, Socioeconomic Factors, United States, Cohort Studies, Smoking Cessation, Nicotinic Agonists, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.